Treatment of brain gliomas with checkpoint inhibitor antibodies to cytotoxic Tlymphocyte-associated antigen 4 (a-CTLA-4) and programmed cell death-1 (a-PD-1) was largely unsuccessful due to their inability to cross the blood-brain barrier (BBB). We describe a new generation of nano immunoconjugates (NICs) developed on natural biopolymer scaffold, poly(β-L-malic acid), with covalently attached a-CTLA-4 and/or a-PD-1 for delivery across the BBB and activation of local brain anti-tumor immune response in glioma-bearing mice. NIC treatment of mice bearing intracranial GL261 glioblastoma (GBM) resulted in an increase of CD8+ T-cells with a decrease of T regulatory cells (Tregs) in the brain tumor area. Survival of GBM-bearing mice treated with combination of NICs was significantly longer compared to animals treated by single
checkpoint inhibitor-bearing NICs or free a-CTLA-4 and a-PD-1. Our study demonstrates trans-BBB delivery of nanopolymer-conjugated checkpoint inhibitors as an effective treatment of GBM via activation of both systemic and local brain tumor immune response.
Keywords: Nano immunology, checkpoint inhibitors, CTLA-4, PD-1, nano immunotherapy, nanomedicine, glioblastoma multiforme Glioblastoma multiforme (GBM), the most aggressive brain glioma, has seen only small treatment advances in the last 30 years. Treatment options are limited, in part because of inefficient drug delivery across the blood-brain barrier (BBB). Immunotherapy is one of the fastest developing approaches in clinical oncology. However, the unique immune enviroment of the central nervous system (CNS) needs consideration when pursuing immunotherapeutic approaches for gliomas. Advances in nanotechnology allow the design of nanocarriers for targeted delivery of cancer vaccines and chemoimmunotherapies 1 . We combine achivements in nanotechnology and immunotherapy into a new approach to deliver drugs across the BBB and treat glioblastoma multiforme.
Blockade of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) using the antagonistic monoclonal antibody (mAb) ipilimumab was the first strategy to achieve a significant clinical benefit for stage IV melanoma patients 2, 3 . Humanized mAbs against immune system response modulators CTLA-4 (ipilimumab), and programmed cell death-1 (PD-1) (pembrolizumab and nivolumab), received FDA approval. Their effect is due to the suppression of T regulatory cells (Tregs) and activation anti-tumor immune response by cytotoxic T lymphocytes (CTLs). Systemic administration of CTLA-4 or PD-1 and programmed cell death ligand 1 (PD-L1) mAbs can suppress some tumors, but has low efficacy against brain and breast tumors 4, 5 .
Despite growing evidence to support an interaction between the CNS and the systemic immune system 6 , clinical trials using nivolumab and ipilimumab in GBM showed serious safety issues, but not a significant anti-tumor treatment effect 7 . Although CTLA-4 and PD-1 antibodies do not cross the BBB 8, 9, 10 , a modest efficacy has been demonstrated against GBM, possibly due to general immune system activation. A recently published review 11 summarized the results of several immunotherapy clinical trials in glioma: 28 clinical trials for vaccines (e.g., a peptide vaccine that targets EGFRvIII or IDH1); 13 clinical trials completed for oncolytic viruses; 15 phase III clinical trials for checkpoint inhibitors (e.g., CheckMate 143 trial) and genetically modified T cells expressing chimeric antigen receptors (CAR-T cells). Unfortunately, no treatment so far has been superior to the standard-of-care for GBM, represented by temozolomide/radiation therapy with 14.6 months survival. This demonstrates serious unmet need for a novel technological approach. Here we use a versartile drug carrier, poly(β-L-malic acid) (PMLA), a natural polymer obtained from the slime mold Physarum polycephalum 12 , to deliver covalently conjugated CTLA-4 and PD-1 antibodies (a-CTLA-4 and a-PD-1) to brain tumor cells. PMLA-based nanotherapeutics can target brain tumors by crossing the BBB using transferrin receptor (TfR) mediated transcytosis 12, 13 . To our knowledge, this is the first successful use of polymer-based nanocarriers with covalently attached immunotherapeutics to activate local immune response and treat brain tumors.
Results

NICs synthesis
We covalently attached checkpoint inhibitor antibodies, a-CTLA-4 IgG2b or a-PD-1 IgG, to the PMLA backbone to reach stability for plasma circulation. mPEG5000 was attached for solubility and stability, anti-mouse TfR antibody (a-msTfR), to cross the BBB, and trileucine (LLL), for stabilization of PMLA against hydrolytic degradation 14 , hydrophobization, and for endosomolytic drug delivery 15, 16 . Synthesis has been adapted from previous studies 12, 13, 14, 15, 16 with new analysis specific to our NICs ( Fig. 1 ) that have met physicochemical and immunological criteria for translational usage.
Synthesis of NICs for polymer conjugated a-CTLA-4, as an example, involved synthesis of pre-conjugate P/mPEG5000(2%)/LLL(40%)/MEA(10%), chemical activation of mAb maleimide, a-CTLA-4-PEG3400-maleimide, and a-msTfR-PEG3400-maleimide, and conjugation of pre-conjugate with activated mAbs through thiol ether formation ( Fig. 1a ).
This was followed by blocking residual free thiol groups. Size-exclusion HPLC (SE-HPLC) confirmed conjugation ( Fig. 1b-c ). Fourier transform infrared spectroscopy (FTIR) and pull-down ELISA further validated the structure of P/mPEG5000(2%)/LLL(40%)/a-msTfR(0.2%)/a-CTLA-4(0.2%) (P/a-CTLA-4) ( Fig. 1d , f; Supplementary Fig. 1a , c) and P/mPEG5000(2%)/LLL(40%)/a-msTfR(0.2%)/a-PD-1(0.2%) (P/a-PD-1) ( Fig. 1e , g; Supplementary Fig. 1b, d) .
Free a-CTLA-4, a-PD-1, and a-msTfR showed somewhat higher binding affinity toward their respective antigens on a plate surface compared with polymer-bound antibodies, due to the bulkier size of the NICs. In addition, we proved the presence of pairs of two antibodies (i.e. a-CTLA-4 and a-msTfR or a-PD-1 and a-msTfR) within one single polymer chain using pull-down ELISA ( Fig. 1f -g, Supplementary Fig. 1c-d ). The ELISA intensity of a-msTfR on P/a-CTLA-4 conjugate was comparable to that of a-CTLA-4 on the same conjugate, confirming the presence of both a-msTfR and a-CTLA-4 on the conjugate (Fig.1d ). Similar results were obtained for P/a-PD-1, when the surface was coated with PD-1 (Fig.1f ), and for P/a-CTLA-4 and P/a-PD-1, when the surface was coated with msTfR ( Supplementary Fig. 1a-b ). ELISA results confirmed the reactivity of each antibody and the presence of each antibody in the conjugates. FTIR analysis for P/a-CTLA-4 shows peaks at the O-H stretching frequencies of 2880 cm -1 (carboxylic acid O-H) that can be seen in both pre-and final nanoconjugate, as well as peaks that are present at the a-CTLA-4 spectrum, which are also present in the final NIC (mainly peaks at 3270 and 2953 cm -1 , which are N-H and O-H stretching frequencies, and lower frequencies peaks at 1120 and 1630 cm -1 ) ( Supplementary Fig. 2a ). A similar trend could also be seen for P/a-PD-1, with significant specific peaks at 2875, 1664, 1031, and 942 cm -1 ( Supplementary Fig. 2b ). The analysis of the FTIR spectra suggested that the antibodies were conjugated successfully to the pre-conjugate.
ζ-Potentials of NICs were in the range of -9.9 to -11.0 mV, reflecting the design and the intrinsic antibody charges, hydrodynamic size was in the range of 28.0 to 28.5 nm by intensity, in agreement with design and molecular masses of constituents and the absence of aggregates, and endotoxin level was reduced below 0.1 EU/mL by phase separation method 17 (Tab. 1).
NICs cross the BBB and reach the tumor interstitium
Rhodamine-labeled NICs ( Fig. 2a-b) were detected in the brain of tumor-bearing mice, 4h after intravenous (i.v.) injection. NICs were distributed throughout the tumor area, mostly outside the blood vessels, with only occasional presence in the vessels.
Rhodamine-labeled a-CTLA-4 and a-PD-1 could not be detected in the brain at 4h and 6h after i.v. injection, indicating their inability to cross the BBB and reach the brain parenchyma ( Fig. 2c-d ). Conversely, NICs cross the BBB, hence allowing conjugated mAbs to bind to CTLA-4 and PD-1 and modulate the immune response in the tumor area ( Fig. 2e-f ).
NIC treatments increase survival of GL261 glioblastoma-bearing mice
Most preclinical studies with checkpoint inhibitors used intraperitoneal (i.p.) administration of therapeutics 18, 19 , to avoid anaphylactic shock after i.v. injection.
However, systemic i.v. drug administration is widely considered as the clinically accepted method in brain cancer treatment. In animal models, we observed a rapid and fatal hypersensitivity reaction with repeated i.v. injections of a-CTLA-4, a-PD-1, and NICs during our initial experiments. Therefore, to avoid acute immune-mediated anaphylaxislike side effects, premedication must be used 20, 21, 22 .
Although the first two i.v. treatments did not cause any noticeable side effects, mice experienced a severe drop in body temperature, piloerection, loss of spontaneous activity, dyspnea, and lethargy 15-20 min after the following injections. As much as 20% of mice died after the third treatment and up to 100% after the fifth treatment. Different regimens were explored to reduce treatment dosage and frequency, however, without eliminating toxicity (data not shown). To counteract these side effects, 10 mg/kg antihistamine Triprolidine and/or 5 mg/kg platelet activating factor (PAF) antagonist CV6209
were administered prior to each drug injection following the first one. Although both Triprolidine and CV6209 reduced side effects to some level, only when administered in our new combination regimen, they prevented side effects in 100% of cases (data not shown). Premedication allowed 5 repeated i.v. treatments using a 10 mg/kg antibody dose, fully comparable to the current clinical dosage of checkpoint inhibitor mAbs.
Survival of mice bearing intracranial GBM GL261 and treated with free mAbs or NICs alone or in combination was investigated. Both a-CTLA-4 and a-PD-1 failed to increase survival compared to PBS treatment. Crucially, both P/a-CTLA-4 and P/a-PD-1 ( Fig. 3a- b) significantly improved animal survival compared to PBS (p=0.0076 and p=0.0017, respectively) or the respective free antibody treatment (p=0.0362 and p=0.0036, respectively) ( Fig. 3d-e ). A combination of P/a-CTLA-4+P/a-PD-1 further improved survival in GL261 tumor-bearing mice compared to PBS (p<0.0001), a-CTLA-4 (p<0.0001), a-PD-1 (p<0.0001), P/a-CTLA-4 (p<0.0001), and P/a-PD-1 (p=0.0033) ( Fig. 3d-e; Supplementary Fig. 3 ; Supplementary Video).
NICs activate local brain immune response
Flow cytometry analysis showed an expansion of the CD8+ T cell population in the tumor tissue after treatment with NICs, especially in animals treated with P/a-PD-1, compared to PBS and free mAb treatments ( Fig. 4a ). On the contrary, the Treg fraction (CD4+FoxP3+) decreased in all NIC groups compared to PBS and free mAb ( Fig. 4b ).
CD8+ T cells are cytotoxic lymphocytes that carry out the attack and kill tumor cells via different pathways, whereas Tregs are regulatory lymphocytes modulating the immune system to maintain tolerance to self-antigens. Animals with survival longer than the median survival for their treatment group showed larger differences in Treg population between treatments ( Fig. 4c ). Combination therapy achieved the highest reduction in the Treg fraction (Treg fraction = 32.87% for P/a-CTLA-4 + P/a-PD-1 vs. 51.43% for PBS), which is in line with significantly increased animal survival.
To independently confirm flow cytometry data, the local immune system response was investigated with specific CD8 and CD4+FoxP3 immunofluorescence staining of cryosectioned brain tumor tissues. For CD8 staining, we used FIJI software to analyze 4032 cells in tumors from 12 mice representing different treatment groups ( Fig. 5a-g ).
On average, each analyzed image contained 106 ± 22 cells, and cell densities were uniform for all data included in our analysis. We observed a significant increase in the incidence of CD8+ T cells in tumor tissue (F=5.826; p=0.0006) ( Fig. 5g ). In particular, the percentage of CD8+ T cells in drug vs. PBS groups was significantly increased following treatments with P/a-PD-1 (p=0.0213) and P/a-CTLA-4 + P/a-PD-1 (p=0.0005).
No other treatment showed a statistically significant change in the incidence of the CD8+ T cells when compared to the PBS. However, a statistically significant increase in the percentage of CD8+ T cells was also observed when comparing a-CTLA-4 (p=0.0118) and P/a-CTLA4 (p=0.0340) with the P/a-CTLA-4 + P/a-PD-1 condition ( Fig.   5g ). This result confirms that the NIC combination treatment is the most effective at recruiting CD8+ T cells into the tumor tissue.
To determine the effect of our drug treatments on CD4+FoxP3+ cells in tumor tissue, we measured the number of CD4/FoxP3 double immunolabeled T cells. Cells that were exclusively FoxP3+ were not included in our analysis. We analyzed 4736 cells in tumor tissues from 12 mice (2 mice per treatment group) ( Fig. 5h -n). On average, each analyzed image contained 118 ± 20 cells; cell densities were uniform. We observed a significant decrease in the incidence of CD4+FoxP3+ T cells in tumor tissue (F=7.02; p=0.0001) ( Fig. 5n ). Specifically, we observed a significantly lower percentage of CD4+FoxP3+ T cells following treatment with P/a-PD-1 (p=0.0235) and P/a-CTLA-4 + P/a-PD-1 (p=0.0013) when compared to PBS ( Fig. 5n ). Strikingly, this result is almost exactly inverse to our observation related to CD8+ T cells. No other drug treatment showed a statistically significant change in the incidence of the CD4+FoxP3+ T cells when compared to PBS. However, a larger reduction of CD4+FoxP3+ T cells was again observed when comparing the a-CTLA-4 with the P/a-CTLA-4 (p=0.0311) and P/a-CTLA-4 + P/a-PD-1 (p=0.0006) treatments ( Fig. 5n ). These data again suggest that our combination treatment is the most effective at inhibiting CD4+FoxP3+ T cells in the tumor tissue.
Collectively, flow cytometry and histology results confirmed that the treatment with NICs stimulated the local brain immune system allowing cytotoxic T cells to attack the tumor.
NICs increase systemic immune response
When activated, CD4+ and CD8+ T cells produce inflammatory cytokines. To confirm systemic immune activation following NIC treatment, serum cytokine levels were measured by multiplex assay. Treatment with P/a-CTLA-4 showed increase of serum levels for multiple interleukins: IL-1β (p<0.01), IL-2 (p<0.01), IL-4 (p<0.01), IL-5 (p<0.01), and IL-12(p70) (p<0.01) ( Supplementary Fig. 3a-d, g) . In contrast, after treatment with P/a-PD-1, only serum levels of IL-2 increased significantly (p<0.01) in comparison with PBS-treated group ( Supplementary Fig. 3b ). The highest increase for all 9 cytokines measured was seen for the combination treatment with P/a-CTLA-4 + P/a-PD-1 vs. PBS treatment: IL-1β (p<0.0001), IL-2 (p<0.0001), IL-4 (p<0.001), IL-5 (p<0.01), IL-6 (p<0.01), IL-10 (p<0.01), IL-12(p70) (p<0.05), IFN-γ (p<0.01), and TNF-α (p<0.05) ( Supplementary Fig .3a -i). These data suggest that the systemic immune response was also activated by our drug treatment.
Discussion
The Immuno-Oncology Translational Network is the number one program on the list of multi-disciplinary, collaborative approaches to accelerate understanding of the tumor immune microenvironment in response to NIH/NCI Blue Ribbon Panel report 23 .
We developed polymeric NICs with covalently attached checkpoint inhibitor mAbs a-CTLA-4 and a-PD-1. They were able to cross the BBB via the proven delivery system using polymer-conjugated a-msTfR 15, 16 , and elicit anti-tumor immune responses in brain glioma in a mouse model. NICs were immunochemically investigated for their biological ability to bind substrates, mimicking the natural conditions for naked a-CTLA-4 and a-PD-1. The analytical results were satisfactory to move to the delivery and therapeutic steps.
The glioma immune microenvironment is very complex, but, with proper checkpoint inhibitor delivery through the BBB, the basic concept for immune treatment still holds true: disrupting the PD-1/PD-L1 and CTLA-4/B7-1 complex formation in the tumor is key to the improved survival of glioma-bearing mice.
Checkpoint inhibitors have shown clinical efficacy for the treatment of "hot" immunogenic tumors, such as melanoma and other cancers with high rate of lymphocyte infiltration, when GBMs are considered "cold" and poorly infiltrated with lymphocytes 11, 24 . The most significant obstacles in the treatment with checkpoint inhibitors are tumor resistance and toxicity 25 , as well as their inability to cross biological barriers such as the BBB 8 . GBM, a very aggressive tumor with short survival and with limited and poorly effective treatment options, presents a particular challenge for drug delivery because of its location in the CNS and the necessity for the drugs to cross the BBB. A recent study has described survival improvement and immune system activation in glioma-bearing mice treated with free checkpoint inhibitor mAbs (a-PD1 and a-CTLA-4) 26 . Although such antibodies do not bind known receptors capable of BBB transcytosis and are unlikely to function effectively in the brain, they may still provide a modest activation of the brain immune system, possibly working through systemic immune stimulation 8, 10, 25 .
For the first time, we demonstrated the efficacy of NICs carrying a-PD-1 and a-CTLA-4 in treating GBM in a murine model vs. free a-CTLA-4 and a-PD-1. We established that NICs, as single nano agent therapies and, especially, as a combination of P/a-PD-1 + P/a-CTLA-4, cross the BBB and significantly increase survival of GL261 tumor-bearing mice activating the brain resident immune system compared to treatment with free antibodies (Supplementary Video).
The activation of the resident immune system following NIC treatments was evidenced by a local increase in CD8+ T cells, which are cytotoxic effector T cells that attack the tumor, and a reduction of Tregs, which suppress activation and proliferation of effector T cells. Tregs population in the brain tumor significantly decreased after NIC treatments compared to PBS and free mAbs.
As a consequence of immune system activation, serum levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, and IFN-γ were significantly increased after combination treatment with P/CTLA-4 + P/PD-1 compared to other treatments. Cytokines are produced by T cells to regulate immune response and to kill cancer cells through apoptotic and non-apoptotic pathways 27 .
In general, IL-1β, IL-2, IL-12, IFN-γ, and TNF-α are part of T helper 1 (Th1) response, whereas IL-4, IL-5, IL-6, and IL-10 are part of T helper 2 (Th2) response. IL-2 secretion promotes T and B lymphocyte activity, enhances anti-tumor immunity, stimulates microglia, and regulates Tregs 28, 29, 30 . IFN-γ is mainly produced by CD4+ and CD8+ T cells, NK cells, and microglia to boost the cytotoxic immune response 30, 31 . In a selfstimulating loop, the microglia can also secrete IL-12, activating NK and stimulating T cells 32 . Conversely, IL-10 is a multifunctional immune cytokine with anti-angiogenic properties 33, 34 . Finally, cytokines like IL-1β and TNF-α can suppress tumors via stimulation of cell-mediated humoral immune reaction 35 . In our study, all these cytokines are elevated in serum of animals treated with NIC combination, supporting increased cytotoxic activity of the immune system. Some of these cytokines have been used in anti-cancer treatment: IL-4 for GBM 36, 37 IL-12 for breast cancer brain metastasis 38 , IL-2 for melanoma brain metastasis 39, 40 , and IFN-α and IL-2 for renal cell carcinoma 41 .
CTLA-4 and PD-1 suppression also increased IL-4, IL-5, IL-6, and IL-10, which is a known effect of such treatments in other cancer types 42, 43, 44 .
Two pathways of anaphylaxis are known in mice: one is caused by antigen crosslinking of IgE on mast cells followed by release of histamine 45, 46 , and the second one is mediated by IgG1 and basophil or neutrophil release of PAF 20, 47 . Immunotherapy with a-CTLA-4 and a-PD-1 caused anaphylaxis-like side effects after repeated administrations. However, we observed absence of adverse effects after premedication consisting of anti-histamine, Triprolidine, and PAF antagonist, CV6209, previously shown to prevent anaphylaxis in other contexts 22 .
In our study, premedication safely allowed for 5 repeated i.v. administrations at a therapeutic dosage comparable with the clinical settings. PAF inhibitor drugs are currently available for clinical use in cardiac rehabilitation and could be adopted in future clinical trials to mitigate adverse immune-mediated events related to checkpoint inhibitor therapy 22 .
Overall, our results show that BBB-crossing NICs stimulate the brain resident immune system, prompting the proliferation of CD8+ T-cells and triggering the release of several cytokines, thus orchestrating immune response against glioblastoma. These NICs provide a novel and useful tool for the delivery of immunotherapy and targeted therapies to brain tumors. They may be used for treatment of primary brain tumors and brain metastases, where current treatment is very inefficient 48, 49 due to the inability to deliver therapeutics through the BBB and activate brain privileged immune system.
A new regimen of premedication appears to alleviate adverse immune-mediated effects upon repeated i.v. injections of NICs, allowing the use of this clinically relevant route of administration in animal studies of checkpoint inhibitors.
Methods
Reagents
Polymalic acid (PMLA) with molecular mass 50,000 D (SEC-HPLC/polystyrene sulfonate standards, polydispersity 1.2) was isolated from the culture supernatant of Physarum polycephalum M3CVII as previously described 14, 50 . Mal-PEG3400-Mal and mPEG5000-NH2 were obtained from Laysan Bio (Arab, AL). Cy5.5 maleimide was obtained from Lumiprobe (Hallandale Beach, FL, USA). Superdex G-75 was obtained from GE Healthcare (Uppsala, Sweden). InVivoMAb anti-mouse PD-1 (clone j43, Isotype Armenian hamster IgG) was from BioXcell (West Lebanon, NH) and mouse antimouse a-CTLA-4 IgG2b (clone 9D9) was from Bristol-Myers Squibb (Redwood City, CA).
Synthesis of NICs
Synthesis of P/mPEG5000(2%)/LLL(40%)/2-mercapto-ethylamine (pre-conjugate).
Pre-conjugate P/mPEG5000(2%)/LLL(40%)/2-mercapto-ethylamine was synthesized based on the method previously described 12, 13, 15 . At first, the pendant polymer carboxylates were converted into highly reactive NHS ester from N-hydroxysuccinimide (NHS), dicyclohexylcarbodiimide (DCC) (1:1:1 molar ratio for PMLA-COOH:NHS:DCC ) in acetone/DMF (1:1, 20 o C, 2 h). The ester was then substituted by amidations following the addition of mPEG5000-NH2 (2% equivalent to the total malyl groups in 200 µL DMF; 1 h), H-Leu-Leu-Leu-OH (LLL) (40% dissolved in DMF with 1.1 equivalent of trifluoroacetic acid to LLL for solubilization, added in 6 portions at 10min intervals, each followed by aliquots of 1.1 equivalent of trimethylamine to LLL), 2-mercaptoethylamine (MEA) (10%, DMF, 30 min, together with DTT 2 equivalent to MEA, followed by 1 equivalent triethylamine). The completion of each reaction was controlled by ninhydrin test. After hydrolysis of unreacted NHS ester by the addition of phosphate buffer (100 mM, pH 6.8), precipitation of dicyclohexylurea and removal by filtration, the pre-conjugate P/mPEG5000(2%)/LLL(40%)/MEA(10%) was purified over PD-10 column (GE Healthcare, Pasadena, CA) and lyophilized (Fig.1a ). 
Synthesis of a-
Synthesis of P/mPEG5000(2%)/LLL(40%)/a-CTLA-4(0.2%)/a-msTfR(0.2%) and P/mPEG5000(2%)/LLL(40%)/a-PD-1(0.2%)/a-msTfR(0.2%)
To the mixture of a-CTLA-4-PEG3400-Maleimide (or a-PD-1-PEG3400-Maleimide) and a-msTfR-PEG3400-Maleimide (10 mg each, equal to 0.2% equivalent to total malyl groups) in 4 mL 100 mM sodium phosphate buffer (100 mM, pH 6.3) pre-conjugate (P/mPEG5000(2%)/LLL(40%)/2-mercapto-ethylamine 2.5 mg/mL; 11.7 mg, in 4 mL of phosphate buffer) was added dropwise. Successful conjugation (30 min, 20 o C) was confirmed by SE-HPLC. In the case of fluorescent labeling, rhodamine-Mal (1% equivalent of total malyl groups) was conjugated with the polymer backbone. After conjugation was completed, excess of pyridyl dithiopropionate (PDP) was added to block remaining sulfhydryl groups (30 min, 20 o C). The volume was adjusted to 4 mL by centrifugation over Vivaspin 20 and the product was purified over PD-10 column (in PBS). After removal of endotoxin using Triton X-114 17 , conjugates P/mPEG5000(2%)/LLL(40%)/a-CTLA-4(0.2%)/a-msTfR(0.2%) (P/a-CTLA-4) ( Fig. 3a) and P/mPEG5000(2%)/LLL(40%)/a-PD-1(0.2%)/a-msTfR(0.2%) (P/a-PD-1) (Fig. 3b) were aliquoted and stored at -20 o C.
Size-exclusion HPLC
The synthesis of NICs were monitored with Hitachi HPLC system equipped with diode The samples (a-CTLA-4, a-PD-1, a-msTfR, and nanoconjugates P/a-CTLA-4 or P/a-PD-1) were incubated in binding buffer containing 0.5% milk for 1 h followed by washing four times. Secondary HRP-labeled antibodies (goat anti-rat from Abcam, Cambridge, MA, goat anti-mouse and goat anti-hamster antibodies from SeraCare) were used for detection of free and conjugated a-msTfR and conjugated a-CTLA-4 or a-PD-1. The conjugated a-msTfR was detected with anti-rat/HRP secondary antibody when the other antibody a-CTLA-4 or a-PD-1 was attached to its plate-adsorbed antigen, to confirm the presence of both antibodies on one polymer chain (pull-down ELISA). Pull-down ELISA was also performed for detection of a-CTLA-4 or a-PD-1 when the other antibody a-msTfR was attached to its plate-adsorbed antigen similarly.
Hydrodynamic diameter and ζ potential measurement
The NICs were characterized with respect to their size (hydrodynamic diameter) using a Malvern Zetasizer Nano (Malvern Instruments, UK). The diameter that is measured in DLS (Dynamic Light Scattering) refers to the particle diffusion within a fluid and is referred to as the hydrodynamic diameter corresponding to the diameter of a sphere that has the same translational diffusion coefficient as the NICs. All calculations were carried out using the Zetasizer 7.0 software. For the NIC size and ζ-potential measurements, the solutions were prepared in PBS at the concentration of 1-2 mg/mL after 0.2 μm membrane filtration. All copolymer solutions were prepared immediately before analysis at 25°C. Data represent the mean value obtained from three independent measurements.
Malic acid assay
The content of PMLA in NICs was estimated by quantitative measurement of the malic acid produced after hydrolysis of NICs based on the photometric or fluorometric 
Immunostaining for drug delivery through BBB and T cell identification
For drug delivery experiments, tumor bearing mice alternatively injected with rhodamine-labeled NICs (P/a-CTLA-4 or P/a-PD-1) or rhodamine-labeled free mAbs (a-CTLA-4 or a-PD-1) were euthanized 4 h after injection. For T cell staining, tumorbearing mice were alternatively treated with NICs (P/a-CTLA-4 or P/a-PD-1) or free antibodies (a-CTLA-4 or a-PD-1) and euthanized 24 h after the third treatment. In both drug delivery and T cell staining experiments, brains were embedded in OCT and sectioned using a Leica CM3050 S cryostat (Leica Biosystems, Buffalo Grove, IL).
Tissue sections were air-dried at room temperature, fixed with 1% paraformaldehyde for Optical imaging data were analyzed using FIJI software 51 . Images acquired at 40X or 63X magnification were first normalized for size. This was done by cropping the 40X images (85% of data) to a dimension that equaled the 63X image. The position of the crop was randomized so that cells included in the final analysis were objectively selected. Total cell numbers were calculated from manual counts of DAPI-labeled nuclei; counts were performed with the FIJI cell counter tool. Cells that were labeled with anti-CD8, anti-CD4 and anti-FoxP3 antibodies were counted separately by two investigators, and ratios were calculated against the number of DAPI-labeled cells. We 
